| Clinical validation of the tempus xT next-generation targeted oncology sequencing assay N Beaubier, R Tell, D Lau, JR Parsons, S Bush, J Perera, S Sorrells, ... Oncotarget 10 (24), 2384, 2019 | 140 | 2019 |
| Integrated genomic profiling expands clinical options for patients with cancer N Beaubier, M Bontrager, R Huether, C Igartua, D Lau, R Tell, AM Bobe, ... Nature biotechnology 37 (11), 1351-1360, 2019 | 130 | 2019 |
| Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort BD Leibowitz, BV Dougherty, JSK Bell, J Kapilivsky, J Michuda, ... BMC cancer 22 (1), 587, 2022 | 24 | 2022 |
| Systems and methods for multi-label cancer classification J Michuda, KA Beauchamp, J Kapilivsky, C McCarter, N Beaubier, ... US Patent 11,527,323, 2022 | 13 | 2022 |
| Disease diagnostics using machine learning of immune receptors ME Zaslavsky, E Craig, JK Michuda, N Sehgal, N Ram-Mohan, JY Lee, ... Biorxiv, 2022.04. 26.489314, 2022 | 12 | 2022 |
| Use of clinical RNA-sequencing in the detection of actionable fusions compared to DNA-sequencing alone. J Michuda, BH Park, AL Cummings, S Devarakonda, B O'Neil, S Islam, ... Journal of Clinical Oncology 40 (16_suppl), 3077-3077, 2022 | 9 | 2022 |
| Systems and methods for multi-label cancer classification J Michuda, KA Beauchamp, J Kapilivsky, C McCarter, N Beaubier, ... US Patent App. 17/150,992, 2021 | 9 | 2021 |
| Validation of a transcriptome-based assay for classifying cancers of unknown primary origin J Michuda, A Breschi, J Kapilivsky, K Manghnani, C McCarter, ... Molecular Diagnosis & Therapy 27 (4), 499-511, 2023 | 7 | 2023 |
| Transcriptome-based cancer type prediction for tumors of unknown origin. J Michuda, C Igartua, T Taxter, JSK Bell, R Pelossof, K White Journal of Clinical Oncology 37 (15_suppl), 3081-3081, 2019 | 6 | 2019 |
| Comprehensive validation of RNA sequencing for clinical NGS fusion genes and RNA expression reporting J Hu, J Parsons, B Mineo, JSK Bell, J Malinauskas, J Drews, J Michuda, ... Cancer Res 81 (13 Supplement), 2239, 2021 | 4 | 2021 |
| Methods of normalizing and correcting rna expression data K Shah, A Hafez, C Igartua, J Michuda US Patent App. 16/581,706, 2020 | 4 | 2020 |
| Robust detection of sequencing batch effects in RNA through low dimensional embedding with subtype-matched reference samples J Drews, J Bell, W Munson, S Saini, B Leibowitz, J Michuda, C McCarter, ... Cancer Research 80 (16_Supplement), 5466-5466, 2020 | 2 | 2020 |
| Multimodal prediction of diagnosis for cancers of unknown primary J Michuda, B Leibowitz, S Amar-Farkash, C Bevis, A Breschi, J Kapilivsky, ... Cancer Research 80 (16_Supplement), 5423-5423, 2020 | 2 | 2020 |
| Systems and methods for multi-label cancer classification J Michuda, KA Beauchamp, J Kapilivsky, C McCarter, NT Beaubier, ... US Patent App. 17/982,399, 2023 | 1 | 2023 |
| 923P Molecular classification of cancers of unknown primary expands and refines treatment options DJ George, E Moore, GC Blobe, N DeVito, BA Hanks, MR Harrison, ... Annals of Oncology 33, S968-S969, 2022 | 1 | 2022 |
| Assessing the utility of molecular diagnostic classification for cancers of unknown primary EC Moore, GC Blobe, NC DeVito, BA Hanks, MR Harrison, CJ Hoimes, ... Cancer Medicine 12 (19), 19394-19405, 2023 | | 2023 |
| Methods and systems for detecting alternative splicing in sequencing data A Breschi, JSK Bell, J Drews, B Leibowitz, J Michuda US Patent App. 17/963,969, 2023 | | 2023 |
| Transcriptome background tissue correction in metastatic cancers using a correlated composition admixture model C McCarter, B Leibowitz, J Michuda, JS Bell, C Igartua, KP White Cancer Research 80 (16_Supplement), 5481-5481, 2020 | | 2020 |
| Associations between HIV Susceptibility and Mutations in the Vif-associated APOBEC3G Proteasomal Complex K Emancipator, J Michuda, S Penugonda | | |
